Causes and evaluation of mildly elevated liver transaminase levels.

Mild elevations in levels of the liver enzymes alanine transaminase and aspartate transaminase are commonly discovered in asymptomatic patients in primary care. Evidence to guide the diagnostic workup is limited. If the history and physical examination do not suggest a cause, a stepwise evaluation should be initiated based on the prevalence of diseases that cause mild elevations in transaminase levels. The most common cause is nonalcoholic fatty liver disease, which can affect up to 30 percent of the population. Other common causes include alcoholic liver disease, medication-associated liver injury, viral hepatitis (hepatitis B and C), and hemochromatosis. Less common causes include α(1)-antitrypsin deficiency, autoimmune hepatitis, and Wilson disease. Extrahepatic conditions (e.g., thyroid disorders, celiac disease, hemolysis, muscle disorders) can also cause elevated liver transaminase levels. Initial testing should include a fasting lipid profile; measurement of glucose, serum iron, and ferritin; total iron-binding capacity; and hepatitis B surface antigen and hepatitis C virus antibody testing. If test results are normal, a trial of lifestyle modification with observation or further testing for less common causes is appropriate. Additional testing may include ultrasonography; measurement of α(1)-antitrypsin and ceruloplasmin; serum protein electrophoresis; and antinuclear antibody, smooth muscle antibody, and liver/kidney microsomal antibody type 1 testing. Referral for further evaluation and possible liver biopsy is recommended if transaminase levels remain elevated for six months or more.

[1]  Alicja R Rudnicka,et al.  Statin safety: a systematic review. , 2006, The American journal of cardiology.

[2]  T. Ben-Menachem,et al.  Prospective evaluation of unexplained chronic liver transaminase abnormalities in asymptomatic and symptomatic patients , 1999, American Journal of Gastroenterology.

[3]  M. Lazo,et al.  Brief Communication: Clinical Implications of Short-Term Variability in Liver Function Test Results , 2008, Annals of Internal Medicine.

[4]  American Gastroenterological Association medical position statement: evaluation of liver chemistry tests. , 2002, Gastroenterology.

[5]  A. Czaja,et al.  AMERICAN ASSOCIATION FOR THE STUDY OF LIVER DISEASE. DIAGNOSIS AND TREATMENT OF AUTOIMMUNE HEPATITIS , 2002 .

[6]  D. Torres,et al.  Diagnosis and therapy of nonalcoholic steatohepatitis. , 2008, Gastroenterology.

[7]  D. Mikhailidis,et al.  Safety and efficacy of long-term statin treatment for cardiovascular events in patients with coronary heart disease and abnormal liver tests in the Greek Atorvastatin and Coronary Heart Disease Evaluation (GREACE) Study: a post-hoc analysis , 2010, The Lancet.

[8]  J. Senior,et al.  Drug-related hepatotoxicity. , 2006, The New England journal of medicine.

[9]  James H. Lewis,et al.  Efficacy and safety of high‐dose pravastatin in hypercholesterolemic patients with well‐compensated chronic liver disease: Results of a prospective, randomized, double‐blind, placebo‐controlled, multicenter trial , 2007, Hepatology.

[10]  N. Caporaso,et al.  Consensus recommendations for managing asymptomatic persistent non-virus non-alcohol related elevation of aminotransferase levels: suggestions for diagnostic procedures and monitoring. , 2008, Digestive and liver disease : official journal of the Italian Society of Gastroenterology and the Italian Association for the Study of the Liver.

[11]  J. Stockman,et al.  Aminotransferase Elevations in Healthy Adults Receiving 4 Grams of Acetaminophen Daily: A Randomized Controlled Trial , 2008 .

[12]  M. Schilsky,et al.  Diagnosis and treatment of Wilson disease: An update , 2008, Hepatology.

[13]  K. Heard,et al.  Serum Alanine Aminotransferase Elevation During 10 Days of Acetaminophen Use in Nondrinkers , 2010, Pharmacotherapy.

[14]  J. Teckman,et al.  Alpha-1-antitrypsin deficiency: Diagnosis, pathophysiology, and management , 2006, Current gastroenterology reports.

[15]  M. Manns,et al.  Diagnosis and management of autoimmune hepatitis , 2010, Hepatology.

[16]  N. Chalasani Statins and hepatotoxicity: Focus on patients with fatty liver , 2005, Hepatology.

[17]  Greger Lindberg,et al.  Decreased survival of subjects with elevated liver function tests during a 28‐year follow‐up , 2010, Hepatology.

[18]  E. Krawitt Autoimmune hepatitis. , 1996, The New England journal of medicine.

[19]  F. Schaffner,et al.  Nonalcoholic fatty liver disease. , 1986, Progress in liver diseases.

[20]  H. Bays Statin safety: an overview and assessment of the data--2005. , 2006, The American journal of cardiology.

[21]  F. Schick,et al.  Non-invasive assessment and quantification of liver steatosis by ultrasound, computed tomography and magnetic resonance. , 2009, Journal of hepatology.

[22]  Edwin K Silverman,et al.  Clinical practice. Alpha1-antitrypsin deficiency. , 2009, New England Journal of Medicine.

[23]  F. Brancati,et al.  The prevalence and etiology of elevated aminotransferase levels in the United States , 2003, American Journal of Gastroenterology.

[24]  Max Bayard,et al.  Nonalcoholic fatty liver disease. , 2006, American family physician.

[25]  M. Aronson,et al.  Screening for Hereditary Hemochromatosis: A Clinical Practice Guideline from the American College of Physicians , 2005, Annals of Internal Medicine.

[26]  J. Stoker,et al.  The diagnostic accuracy of US, CT, MRI and 1H-MRS for the evaluation of hepatic steatosis compared with liver biopsy: a meta-analysis , 2010, European Radiology.

[27]  Aijaz Ahmed,et al.  The asymptomatic outpatient with abnormal liver function tests. , 2009, Clinics in liver disease.

[28]  R. Green,et al.  AGA technical review on the evaluation of liver chemistry tests. , 2002, Gastroenterology.

[29]  E. Boyko,et al.  The Prevalence and Predictors of Elevated Serum Aminotransferase Activity in the United States in 1999–2002 , 2006, The American Journal of Gastroenterology.

[30]  M. Kaplan,et al.  Evaluation of abnormal liver-enzyme results in asymptomatic patients. , 2000, The New England journal of medicine.

[31]  H. Popper American Association for the Study of Liver Diseases: Symposium on Toxic Hepatic Injury , 1960 .